David Peereboom

10PUBLICATIONS
78CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Mining, energy and natural resources lawMolecular targetsGene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Oct 01, 2026
Efficacy and safety of tirabrutinib monotherapy for relapsed/refractory primary CNS lymphoma: PROSPECT phase 2 trial.

|Jun 22, 2026
Phase 2 study of regorafenib in patients with progressive glioblastoma after failure of bevacizumab.

|Jan 23, 2026
Role of Immunotherapy and Targeted Agents to Treat Brain Metastases.

Nicole Hajdari, David M Peereboom

|Dec 01, 2025
STELLAR: Phase III, Randomized, Open-Label Study of Eflornithine Plus Lomustine Versus Lomustine Alone in Patients With Recurrent Grade 3 Astrocytoma.

Howard Colman, Giuseppe Lombardi, Eric T Wong

|Jan 17, 2025
Phase I Study of Adavosertib with Radiotherapy and Temozolomide in Newly Diagnosed Glioblastoma and Intratumoral Drug Levels in Recurrent Glioblastoma.

Eudocia Q Lee, Brian M Alexander, Carlos G Romo

|Jun 05, 2024
Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT.

Manmeet S Ahluwalia, Ahmad Ozair, Jan Drappatz

Pageof 2

Frequent Collaborators

4 joint publications

Manmeet S Ahluwalia

3 joint publications

Louis B Nabors

3 joint publications

Jorg Dietrich

3 joint publications

Patrick Y Wen